VistaGen Therapeutics, Inc. (VTGN) Financials
VTGN Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 35.7 million | 11.3 million |
| March 31, 2026 | 48.6 million | 13.0 million |
| Dec. 31, 2025 | 65.1 million | 14.1 million |
| Sept. 30, 2025 | 80.9 million | 14.6 million |
VTGN Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -14.7 million | 991000 |
| March 31, 2026 | -16.2 million | 889000 |
| Dec. 31, 2025 | -17.6 million | 1.1 million |
| Sept. 30, 2025 | -13.8 million | 1.1 million |
VTGN Net Income
No data available :(
VTGN Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 31.7 million | - | - |
| March 31, 2026 | 45.4 million | - | 948000 |
| Dec. 31, 2025 | 61.8 million | - | 1.0 million |
| Sept. 30, 2025 | 77.2 million | - | 1.2 million |
VTGN Shares Outstanding
VTGN Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | - | 10.9 million | 3.9 million | - |
| March 31, 2026 | 125000 | 13.1 million | 4.1 million | - |
| Dec. 31, 2025 | 60000 | 14.2 million | 5.5 million | - |
| Sept. 30, 2025 | 60000 | 15.9 million | 4.4 million | - |
VTGN Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | 1.5 million | 197000 |
| March 31, 2026 | 465000 | 389000 |
| Dec. 31, 2025 | 303000 | 189000 |
| Sept. 30, 2025 | 258000 | - |
VTGN Revenue by Segment
Graph available only for paid members. Upgrade to see it.
VTGN
Price: $0.20
52 week price:
Payout Ratio Range:
Earnings Per Share: -1.66 USD
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 11.3 million
Ebitda: -2.8 millionMarket Capitalization: 12.5 million